Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
63 studies found for:    "Dermatomyositis"
Show Display Options
RSS Create an RSS feed from your search for:
"Dermatomyositis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Efficacy of BAF312 in Dermatomyositis
Condition: Active Dermatomyositis
Interventions: Drug: BAF312 0.5 mg;   Drug: BAF312 2 mg;   Drug: BAF312 10 mg;   Drug: Placebo to BAF312
2 Completed
Has Results
A Pilot Study of Etanercept in Dermatomyositis
Condition: Dermatomyositis
Interventions: Drug: Etanercept;   Drug: Placebo
3 Recruiting Trial of IMO-8400 in Adult Patients With Dermatomyositis
Condition: Dermatomyositis
Interventions: Drug: IMO-8400 Dose Group 1;   Drug: IMO-8400 Dose Group 2;   Drug: Placebo
4 Recruiting Abatacept in Juvenile Dermatomyositis
Condition: Dermatomyositis
Intervention: Drug: Abatacept
5 Terminated Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Condition: Dermatomyositis
Interventions: Drug: Prednisone;   Drug: Methotrexate;   Drug: Etanercept
6 Recruiting Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Conditions: Dermatomyositis;   Juvenile Dermatomyositis
Intervention: Drug: H.P. Acthar Gel
7 Completed Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
Condition: Dermatomyositis
Intervention: Drug: h5G1.1-mAb
8 Recruiting Study of IFN-K in Dermatomyositis
Condition: Dermatomyositis
Interventions: Biological: IFN-Kinoid;   Other: Placebo;   Other: ISA 51
9 Recruiting Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Condition: Dermatomyositis
Intervention:
10 Recruiting Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Condition: Dermatomyositis
Interventions: Drug: JBT-101;   Drug: Placebo
11 Terminated
Has Results
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
Condition: Dermatomyositis
Intervention: Drug: Apremilast
12 Unknown  Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
Condition: Juvenile Dermatomyositis
Interventions: Drug: 3 MPDN pulse + PDN;   Drug: 3 MPDN pulse + PDN + CSA;   Drug: 3 MPDN pulse + PDN + MTX
13 Not yet recruiting Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Condition: Dermatomyositis
Interventions: Drug: Octagam 10%;   Other: Placebo
14 Completed Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Conditions: Dermatomyositis;   Polymyositis
Intervention: Drug: Adrenocorticotropic Hormone Gel
15 Completed A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
Condition: DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: Biological: MEDI-545;   Other: Placebo
16 Recruiting Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Conditions: Dermatomyositis;   Polymyositis
Interventions: Drug: tocilizumab;   Drug: placebo
17 Completed Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
Conditions: Polymyositis;   Dermatomyositis
Interventions: Drug: GB-0998;   Drug: Placebo of GB-0998
18 Enrolling by invitation Dermatomyositis and Polymyositis Registry
Conditions: Dermatomyositis;   Polymyositis
Intervention: Drug: Acthar
19 Completed Hand Function in Patients With Poly- or Dermatomyositis
Conditions: Polymyositis;   Dermatomyositis
Intervention:
20 Completed Methimazole to Treat Polymyositis and Dermatomyositis
Conditions: Dermatomyositis;   Polymyositis
Intervention: Drug: methimazole

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.